✦ LIBER ✦

708 INTERMITTENT CHEMOTHERAPY FOR METASTATIC HORMONE REFRACTORY PROSTATE CANCER: LONG TERM RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL

✍ Scribed by Ozen, Haluk; Akdogan, Bulent; Ergen, Ali; Gunay, Levent Mert; Kirdal, Yeter; Inci, Kubilay; Bilen, Cenk Yucel

Book ID: 123046554
Publisher: Lippincott Williams and Wilkins
Year: 2011
Tongue: English
Weight: 46 KB
Volume: 185
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2011.02.1676

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel, with or without estramustine

Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial

✍ Orazio Caffo; Teodoro Sava; Evi Comploj; Annamaria Fariello; Fable Zustovich; Ro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

Long-Term Outcome of Phase I/II Clinical

Long-Term Outcome of Phase I/II Clinical Trial of Ad-OC-TK/VAL Gene Therapy for Hormone-Refractory Metastatic Prostate Cancer

✍ Shirakawa, Toshiro; Terao, Shuji; Hinata, Nobuyuki; Tanaka, Kazushi; Takenaka, A 📂 Article 📅 2007 🏛 Mary Ann Liebert 🌐 English ⚖ 239 KB

Apatinib for Chemotherapy-Refractory Adv

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

✍ Li, J.; Qin, S.; Xu, J.; Guo, W.; Xiong, J.; Bai, Y.; Sun, G.; Yang, Y.; Wang, L 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 148 KB

Estimating Clinically Meaningful Changes

Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer

✍ David Cella; Michael B. Nichol; David Eton; Joel B. Nelson; Parvez Mulani 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Intermittent Versus Continuous Total And

Intermittent Versus Continuous Total Androgen Blockade in the Treatment of Patients with Advanced Hormone-Naive Prostate Cancer: Results of a Prospective Randomized Multicenter Trial

✍ de Leval, Jean; Boca, Philippe; Youssef, Enis; Nicolas, Hubert; Jeukenne, Michel 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 148 KB

A phase 3 randomized controlled trial of

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro